Here, the results from AMBER part 2B are reported, which evaluated the safety and efficacy of cobolimab in combination with dostarlimab in patients with locally advanced or metastatic NSCLC whose disease had progressed on prior anti–PD-(L)1 treatment. Here, CD274 is linked to non-small cell lung carcinoma.